Tirzepatide is the active ingredient in Zepbound, the FDA approved prescription medicine for Obstructive Sleep Apnea.

Obstructive sleep apnea (OSA) is a common sleep disorder characterized by intermittent airway blockages during sleep, leading ...

However, the machines tend to be ... May 30, 2024 — A new study demonstrates that when individuals with obstructive sleep apnea use their positive airway pressure machine more regularly ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

On December 20, 2024, pharmaceutical company Eli Lilly announced that the FDA approved its first and only obstructive sleep ...

For about 25 million Americans who suffer from obstructive sleep apnea, there are various effective treatments such as CPAP breathing machines, surgery, a dental mouthpiece and even an implantable pac ...

Background: The pathogenesis of daytime hypercapnia (PaCO 2 ≥ 45 mm Hg) may be directly linked to the existence of obstructive sleep apnea syndrome (OSAS) per se, although only some patients ...

OSA impacts about 936 million people worldwide and occurs when the throat muscles relax and block the airway with a common ...

The sleep apnea diagnostic systems market is expected to grow from US$ 4.81 billion in 2023 to US$ 9.27 billion by 2033, at a ...

From sleep apnea-fighting mattresses to smart rings that play lullabies, the best sleep tech from Day 1 of CES 2025 ...

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical ...